Protagonist Therapeutics (PTGX) Payables: 2017-2025
Historic Payables for Protagonist Therapeutics (PTGX) over the last 9 years, with Sep 2025 value amounting to $22.9 million.
- Protagonist Therapeutics' Payables rose 10.27% to $22.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.8 million, marking a year-over-year increase of 2.85%. This contributed to the annual value of $23.7 million for FY2024, which is 22.39% up from last year.
- Latest data reveals that Protagonist Therapeutics reported Payables of $22.9 million as of Q3 2025, which was up 48.52% from $15.4 million recorded in Q2 2025.
- In the past 5 years, Protagonist Therapeutics' Payables ranged from a high of $37.7 million in Q4 2021 and a low of $11.8 million during Q1 2025.
- Over the past 3 years, Protagonist Therapeutics' median Payables value was $19.4 million (recorded in 2023), while the average stood at $18.8 million.
- Per our database at Business Quant, Protagonist Therapeutics' Payables spiked by 113.05% in 2021 and then tumbled by 49.54% in 2023.
- Quarterly analysis of 5 years shows Protagonist Therapeutics' Payables stood at $37.7 million in 2021, then plummeted by 33.83% to $25.0 million in 2022, then declined by 22.43% to $19.4 million in 2023, then rose by 22.39% to $23.7 million in 2024, then grew by 10.27% to $22.9 million in 2025.
- Its Payables was $22.9 million in Q3 2025, compared to $15.4 million in Q2 2025 and $11.8 million in Q1 2025.